Search Result

Results for "

Enterobacteriaceae

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (11) Bacterial (26) Beta-lactamase (8) Penicillin-binding protein (PBP) (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (4) Infection (28) Inflammation/Immunology (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W009168

Tazobactam sodium 5+ Cited Publications	Bacterial Antibiotic	Infection Cancer
Tazobactam sodium is an antibiotic of the beta-lactamase inhibitor class. Ceftolozane combines with Tazobactam, extends the activity of ceftolozane against many ESBL-producing Enterobacteriaceae and some Bacteroides spp..

HY-125604

WCK-4234	Beta-lactamase Bacterial	Infection
WCK-4234 is a potent β-lactamase inhibitor. WCK-4234 inhibits class A, C, and D β-lactamases activity. WCK-4234 lacks direct antibacterial activity. WCK-4234 potentiates imipenem and meropenem against Enterobacteriaceae with OXA-48/OXA-181 or KPC enzymes, or with combinations of impermeability and AmpC or ESBL activity. WCK-4234 distinctively overcomes resistance mediated by OXA-type carbapenemases .

HY-N6665

Cefquinome sulfate	Bacterial Antibiotic	Infection
Cefquinome sulfate is a cephem antibiotic, which inhibits members of the Enterobacteriaceae .

HY-157536

SMT-738	Bacterial	Infection
SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport targeting *Enterobacteriaceae* .

HY-106084

Cefteram T-2525; RO 19-5247; Cefterame	Bacterial	Infection
Cefteram (T-2525) is the free acid of Cefteram pivoxil (HY-106571), which is an orally active cephalosporin ester. Cefteram potently targets to the enteropathogenic Enterobacteriaceae and Vibrionaceae .

HY-19806

Ceftolozane CXA-101 free base; FR264205 free base	Bacterial	Infection
Ceftolozane (CXA-101 free base; FR264205 free base) is a cephalosporin antibiotic with potent activity againstPseudomonas aeruginosa and strains Enterobacteriaceae, with MICs of 0.5 and 0.25-0.5 mg/L .

HY-105393

LB 10517 sodium Antibiotic LB 10517 sodium	Bacterial	Infection
LB 10517 (sodium) is a type of cephalosporin. LB 10517 (sodium) has broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus, and Streptococcus .

HY-150260

SA09-Cu	Bacterial	Infection
SA09-Cu is a noncompetitive and potent NDM-1 inhibitor with an IC₅₀ of 9.6 nM. SA09-Cu can convert NDM-1 into an inactive state by oxidizing the Zn(II)-thiolate site of the enzyme and avoids to be reduced by intracellular thiols of bacteria. SA09-Cu exhibits excellent inhibition against a series of clinical NDM-1-producing carbapenem-resistant Enterobacteriaceae (CRE) in restoring the Meropenem (HY-13678) effect, and slows down the development of carbapenem resistance .

HY-N6665A

Cefquinome	Antibiotic Bacterial	Infection
Cefquinome is a cephem antibiotic, which inhibits members of the Enterobacteriaceae .

HY-N6665R

Cefquinome sulfate (Standard)	Bacterial Antibiotic	Infection
Cefquinome (sulfate) (Standard) is the analytical standard of Cefquinome (sulfate). This product is intended for research and analytical applications. Cefquinome sulfate is a cephem antibiotic, which inhibits members of the Enterobacteriaceae .

HY-123922

NOSO-502	Bacterial	Infection
NOSO-502 is an inhibitor of bacterial translation. NOSO-502 exhibits inhibitory activity against Enterobacteriaceae. NOSO-502 has good safety and antibacterial properties .

HY-B0593

Ceftazidime Maximum Cited Publications 21 Publications Verification GR20263	Beta-lactamase Bacterial Antibiotic	Infection Cancer
Ceftazidime (GR20263), an antibiotic, has a broad spectrum activity against Gram-positive and Gram-negative aerobic bacteria. Ceftazidime is also active against Enterobacteriaceae (including β-lactamase-positive strains) and is resistant to hydrolysis by most β-lactamases .

HY-B0593A

Ceftazidime pentahydrate Maximum Cited Publications 21 Publications Verification GR20263 pentahydrate	Beta-lactamase Bacterial Antibiotic	Infection Cancer
Ceftazidime (GR20263) pentahydrate , an antibiotic, has a broad spectrum activity against Gram-positive and Gram-negative aerobic bacteria. Ceftazidime pentahydrate is also active against Enterobacteriaceae (including β-lactamase-positive strains) and is resistant to hydrolysis by most β-lactamases .

HY-B0593R

Ceftazidime (Standard)	Beta-lactamase Bacterial Antibiotic	Infection
Ceftazidime (Standard) is the analytical standard of Ceftazidime. This product is intended for research and analytical applications. Ceftazidime (GR20263), an antibiotic, has a broad spectrum activity against Gram-positive and Gram-negative aerobic bacteria. Ceftazidime is also active against Enterobacteriaceae (including β-lactamase-positive strains) and is resistant to hydrolysis by most β-lactamases .

HY-16752

Relebactam Maximum Cited Publications 21 Publications Verification MK-7655	Beta-lactamase Bacterial	Infection
Relebactam is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases, including class A (extended-spectrum β-lactamases and KPC) and class C (AmpC) enzymes. Relebactam shows antibacterial activity .

HY-16752R

Relebactam (Standard) MK-7655 (Standard)	Beta-lactamase Bacterial	Infection
Relebactam (Standard) is the analytical standard of Relebactam. This product is intended for research and analytical applications. Relebactam is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases, including class A (extended-spectrum β-lactamases and KPC) and class C (AmpC) enzymes. Relebactam shows antibacterial activity .

HY-122260

S-25932	Bacterial	Infection
S-25932 is a potent 4-quinolones antibacterial agent. S-25932 shows broad gram-negative antibacterial activity. S-25932 shows inhibition for Enterobacter aerogenes, Enterobacter addlomerans, Enterobacter coloacae, Escherichia coli with MIC₉₀ values of 1.0, 2.0, 1.0, 0.25 µg/mL, respectively .

HY-16752A

Relebactam sodium MK-7655 sodium	Beta-lactamase Bacterial	Infection
Relebactam sodium (MK-7655 sodium) is a potent and selective β-lactamase inhibitor with the activity of delaying the development of bacterial resistance to antibiotics. Relebactam sodium can bind to a variety of β-lactamases, thereby improving the efficacy of β-lactam antibiotics. Relebactam sodium shows good application potential in inhibiting complicated bacterial infections .

HY-106668

Isepamicin Sch 21420	Antibiotic Bacterial	Infection
Isepamicin (Sch 21420) is an aminoglycoside antibacterial. Isepamicin has better activity against strains producing type I 6'-acetyltransferase. Isepamicin’s antibacterial spectrum includes Enterobacteriaceae and staphylococci. Anaerobes, Neisseriaceae and streptococci are resistant. Isepamicin exhibits a strong concentration-dependent bactericidal effect, a long post-antibiotic effect (several hours) and induces adaptive resistance .

HY-121329

Carumonam AMA-1080; Ro 17-2301	Penicillin-binding protein (PBP) Antibiotic Bacterial	Infection
Carumonam (AMA-1080; Ro 17-2301) is a sulfonated monocyclic β-Lactam Antibiotic, targeting to penicillin-binding protein (PBP). Carumonam exerts highly activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae, while it weakly and even inactively inhibits Streptococcus pneumoniae and Staphylococcus aureus. Carumonam is resistant to beta-lactamase-mediated hydrolysis .

HY-B0593AR

Ceftazidime pentahydrate (Standard)	Beta-lactamase Bacterial Antibiotic	Infection Cancer
Ceftazidime (pentahydrate) (Standard) is the analytical standard of Ceftazidime (pentahydrate). This product is intended for research and analytical applications. Ceftazidime (GR20263) pentahydrate , an antibiotic, has a broad spectrum activity against Gram-positive and Gram-negative aerobic bacteria. Ceftazidime pentahydrate is also active against Enterobacteriaceae (including β-lactamase-positive strains) and is resistant to hydrolysis by most β-lactamases .

HY-111521

Meropenem-vaborbactam Carbavance	Others	Infection
Meropenem-vaborbactam is an antibiotic against nonfermenting Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistant and carbapenemase genotypes. The susceptibility of Meropenem-vaborbactam (at an inhibitory concentration of 8 μg/ml) and comparators was tested against 14,304 nonfermenting Gram-negative clinical isolates collected worldwide in 2014 by reference broth microdilution. Carbapenemase-encoding genes were screened by PCR and sequencing. At concentrations of ≤1 and ≤2 μg/ml, Meropenem-vaborbactam inhibited 99.1 and 99.3% of the 10,426 Enterobacteriaceae isolates tested, respectively, while Meropenem inhibited 97.3 and 97.7% of these isolates at the same concentrations. For isolates displaying carbapenem-resistant Enterobacteriaceae (CRE) (n = 265), multiagent-resistant (MDR) (n = 1,210), and extensively agent-resistant (XDR) (n = 161) phenotypes, meropenem-vaborbactam had MIC50/90 values of 0.5/32, 0.03/1, and 0.5/32 μg/ml, respectively, while meropenem activity was 16/>32, 0.06/32, and 0.5/32 μg/ml, respectively. Among all geographic regions, activity was highest in the United States against CRE and MDR isolates (MIC50/90, 0.03/1 and 0.03/0.12 μg/ml, respectively). Meropenem-vaborbactam was highly active against 135 KPC-producing isolates, with all isolates inhibited at concentrations ≤8 μg/ml (133 isolates were inhibited at concentrations ≤2 μg/ml). The combination had limited activity against isolates producing metallo-β-lactamases (including 25 NDM-1 and 16 VIM producers) and/or oxocephalosporinases (27 OXA-48/OXA-163 producers), which were mainly found in the Asia-Pacific region and some European countries. Meropenem-vaborbactam had activity comparable to meropenem against Pseudomonas spp., Acinetobacter spp., and Clostridium amylovora. Meropenem-vaborbactam was active against a global collection of contemporary Enterobacteriaceae isolates, and the combination had greater activity against CRE isolates and KPC producers than did meropenem and most comparators, which are often multiagent-resistant.

HY-14879D

ent-Avibactam sodium AVE1330A	Others	Infection
ent-Avibactam sodium (AVE1330A) is a new β-lactamase inhibitor with broad-spectrum antibacterial activity. ent-Avibactam sodium, in combination with ceftazidime, exhibits significant inhibitory effects on Enterobacteriaceae that produce Ambler class A and class C beta-lactamases. The IC₅₀ value of ent-Avibactam sodium is much lower than the commonly used β-lactamase inhibitors clavulanic acid and ticarbonitrile, showing its ability to inhibit TEM-1 and P99 enzyme efficiency .

HY-19936A

ACHN-975 TFA 1 Publications Verification	Bacterial	Infection
ACHN-975 TFA is a selective LpxC inhibitor and exhibits a subnanomolar LpxC inhibitory activity. ACHN-975 TFA is against a wide range of gram-negative bacterias with low MIC values (≤1 μg/mL) .

HY-125579

Ro 25-0534	Bacterial	Infection
Ro 25-0534 is an antimicrobial compound against Pseudomonas. Ro 25-0534 is active against Enterobacteriaceae (MIC₉₀: 0.06-2 μg/mL), Oxacillin (HY-B0465)-susceptible staphylococci, β-hemolytic streptococci, and penicillin-susceptible pneumococci (MIC₉₀: 1-2 μg/mL), Haemophilus influenzae (MIC₉₀: 0.25-0.5 μg/mL), Moraxella catarrhalis (MIC₉₀: 0.5 μg/mL), and most nonenteric Gram-negative bacilli (MIC₉₀: 2-4 μg/mL) .

HY-136072

Xeruborbactam disodium 2 Publications Verification QPX7728 disodium	Bacterial	Infection
Xeruborbactam (QPX7728) disodium is a potent, ultra-broad-spectrum boronic acid beta-lactamase inhibitor. Xeruborbactam disodium inhibits key serine and metallo beta-lactamases at a nano molar range .

HY-136069

Xeruborbactam QPX7728	Bacterial	Infection
Xeruborbactam (QPX7728) is a potent, ultra-broad-spectrum boronic acid beta-lactamase inhibitor. Xeruborbactam inhibits key serine and metallo beta-lactamases at a nano molar range .

HY-106925

Cetefloxacin E 4868	Antibiotic Bacterial	Infection
Cetefloxacin (E 4868) is a board-spectrum antibacterial antibiotic, MIC of 0.007-8 µg/ml. Cetefloxacin exhibits good pharmacokinetic characters in mice. Cetefloxacin exhibits protective effects against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae in mice .

HY-D1056E

Lipopolysaccharides, from P. aeruginosa 10 LPS, from Pseudomonas aeruginosa (10)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides from P. aeruginosa 10 are lipopolysaccharide endotoxins composed of an O-specific antigen chain, a core oligosaccharide, and lipid A. The lipopolysaccharides from P. aeruginosa 10 have a fatty acid composition that differs from that of typical Enterobacteriaceae, with unusually high levels of phosphorylation (with detected triphosphate residues) and a unique external region of the core oligosaccharide, while the O-specific side chains are often rich in novel amino sugars. The susceptibility of Lipopolysaccharides from P. aeruginosa 10 to viruses is related to the high molecular weight polysaccharide content in its components. The absence of high molecular weight polysaccharides increases its sensitivity to bacteriophages .

HY-D1056B3

Lipopolysaccharides, from Klebsiella pneumoniae LPS, from bacterial (Klebsiella pneumoniae)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides, from Klebsiella, are lipopolysaccharide endotoxins. Lipopolysaccharides, from Klebsiella pneumoniae, consist of three parts: lipid A, core oligosaccharide, and O-specific antigen or O-side chain. In smooth LPS, the core region is divided into two areas: the inner core near the lipid A and the outer core that provides attachment sites for the O-antigen. In the lipopolysaccharide of Klebsiella pneumoniae, the l,d-HeppII at the O-3 position can be replaced by an α-d-galacturonic acid residue (α-d-GalpA). In most studied Enterobacteriaceae, the core LPS contains inner core phosphorylation modifications, but the core LPS of Klebsiella pneumoniae lacks this modification. The unique core structure plays an important role in the outer membrane permeability and pathogenesis of Klebsiella pneumoniae .

Cat. No.	Product Name	Type

HY-D1056E

Lipopolysaccharides, from P. aeruginosa 10 LPS, from Pseudomonas aeruginosa (10)	Carbohydrates
Lipopolysaccharides from P. aeruginosa 10 are lipopolysaccharide endotoxins composed of an O-specific antigen chain, a core oligosaccharide, and lipid A. The lipopolysaccharides from P. aeruginosa 10 have a fatty acid composition that differs from that of typical Enterobacteriaceae, with unusually high levels of phosphorylation (with detected triphosphate residues) and a unique external region of the core oligosaccharide, while the O-specific side chains are often rich in novel amino sugars. The susceptibility of Lipopolysaccharides from P. aeruginosa 10 to viruses is related to the high molecular weight polysaccharide content in its components. The absence of high molecular weight polysaccharides increases its sensitivity to bacteriophages .

Lipopolysaccharides, from P. aeruginosa 10

LPS, from Pseudomonas aeruginosa (10)

Carbohydrates

Lipopolysaccharides from P. aeruginosa 10 are lipopolysaccharide endotoxins composed of an O-specific antigen chain, a core oligosaccharide, and lipid A. The lipopolysaccharides from P. aeruginosa 10 have a fatty acid composition that differs from that of typical Enterobacteriaceae, with unusually high levels of phosphorylation (with detected triphosphate residues) and a unique external region of the core oligosaccharide, while the O-specific side chains are often rich in novel amino sugars. The susceptibility of Lipopolysaccharides from P. aeruginosa 10 to viruses is related to the high molecular weight polysaccharide content in its components. The absence of high molecular weight polysaccharides increases its sensitivity to bacteriophages .

HY-D1056B3

Lipopolysaccharides, from Klebsiella pneumoniae LPS, from bacterial (Klebsiella pneumoniae)	Carbohydrates
Lipopolysaccharides, from Klebsiella, are lipopolysaccharide endotoxins. Lipopolysaccharides, from Klebsiella pneumoniae, consist of three parts: lipid A, core oligosaccharide, and O-specific antigen or O-side chain. In smooth LPS, the core region is divided into two areas: the inner core near the lipid A and the outer core that provides attachment sites for the O-antigen. In the lipopolysaccharide of Klebsiella pneumoniae, the l,d-HeppII at the O-3 position can be replaced by an α-d-galacturonic acid residue (α-d-GalpA). In most studied Enterobacteriaceae, the core LPS contains inner core phosphorylation modifications, but the core LPS of Klebsiella pneumoniae lacks this modification. The unique core structure plays an important role in the outer membrane permeability and pathogenesis of Klebsiella pneumoniae .

Lipopolysaccharides, from Klebsiella pneumoniae

LPS, from bacterial (Klebsiella pneumoniae)

Carbohydrates

Lipopolysaccharides, from Klebsiella, are lipopolysaccharide endotoxins. Lipopolysaccharides, from Klebsiella pneumoniae, consist of three parts: lipid A, core oligosaccharide, and O-specific antigen or O-side chain. In smooth LPS, the core region is divided into two areas: the inner core near the lipid A and the outer core that provides attachment sites for the O-antigen. In the lipopolysaccharide of Klebsiella pneumoniae, the l,d-HeppII at the O-3 position can be replaced by an α-d-galacturonic acid residue (α-d-GalpA). In most studied Enterobacteriaceae, the core LPS contains inner core phosphorylation modifications, but the core LPS of Klebsiella pneumoniae lacks this modification. The unique core structure plays an important role in the outer membrane permeability and pathogenesis of Klebsiella pneumoniae .

HY-157356

Violet Red Bile Glucose Agar	Microbial Culture
Violet Red Bile Glucose Agar can be used for counting intestinal bacteria and identification of enterobacteriaceae. The composition of 1 liter of Violet Red Bile Glucose Agar contains: 7.0 g gelatin pancreatic enzyme hydrolysate, 3.0 g yeast extract powder, 1.5 g sodium deoxycholate, 10.0 g glucose, 5.0 g sodium chloride, 0.03 g neutral red, 0.002 g crystal violet, and 15.0 g agar in per liter .

Violet Red Bile Glucose Agar

Microbial Culture

Violet Red Bile Glucose Agar can be used for counting intestinal bacteria and identification of enterobacteriaceae. The composition of 1 liter of Violet Red Bile Glucose Agar contains: 7.0 g gelatin pancreatic enzyme hydrolysate, 3.0 g yeast extract powder, 1.5 g sodium deoxycholate, 10.0 g glucose, 5.0 g sodium chloride, 0.03 g neutral red, 0.002 g crystal violet, and 15.0 g agar in per liter .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.